Your browser doesn't support javascript.
loading
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
Aggarwal, Rahul; Starzinski, Stephanie; de Kouchkovsky, Ivan; Koshkin, Vadim; Bose, Rohit; Chou, Jonathan; Desai, Arpita; Kwon, Daniel; Kaushal, Samuel; Trihy, Lauren; Rastogi, Medini; Ippisch, Robin; Aslam, Maya; Friedlander, Terence; Feng, Felix; Oh, David; Cheung, Alexander; Small, Eric; Evans, Michael; Fong, Lawrence; Hope, Thomas A.
Afiliación
  • Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: rahul.aggarwal@ucsf.edu.
  • Starzinski S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • de Kouchkovsky I; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Koshkin V; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Bose R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Chou J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Desai A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Kwon D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Kaushal S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Trihy L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Rastogi M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Ippisch R; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
  • Aslam M; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
  • Friedlander T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Feng F; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Oh D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Cheung A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Small E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Evans M; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
  • Fong L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Lancet Oncol ; 24(11): 1266-1276, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37922930
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article